A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
Conclusions Concurrent administration of durvalumab and tremelimumab over 1 h is safe with a comparable PK profile to sequential administration.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | History of Medicine | Investigational New Drugs | Study | Toxicology